A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2001
10/25/2001	DE10020125A1 Agent for stimulating bone regrowth, useful as insert after surgery for bone cancer, comprises single sequence expressing a fusion of growth factor and protease inhibitor
10/25/2001	DE10018834A1 Transdermal or transmucosal pharmaceutical dosage form for treatment of nicotine dependence or smoking withdrawal contains nicotine compound or substitute and CNS active compound
10/25/2001	DE10018783A1 Stable aqueous ciprofloxacin infusion solutions containing sulfuric acid as the stabilizing agent useful for the treatment of bacterial infections in humans and animals
10/25/2001	DE10018781A1 Aqueous ciprofloxacin infusion solutions containing orthophosphoric acid monoester or diester as solubilizing and stabilizing agent useful for the treatment of bacterial infections
10/25/2001	CA2747325A1 Albumin fusion proteins
10/25/2001	CA2406590A1 Agent for postoperative use after the removal of bone tumours
10/25/2001	CA2406403A1 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof
10/25/2001	CA2406395A1 High affinity peptide-containing nanoparticles
10/25/2001	CA2406378A1 Targeted vaccine delivery systems
10/25/2001	CA2406226A1 Rapid-onset formulation of a selective cyclooxigenase-2
10/25/2001	CA2405709A1 Albumin fusion proteins
10/25/2001	CA2405701A1 Albumin fusion proteins
10/25/2001	CA2405599A1 Medicaments for treating respiratory disorders comprising formoterol and fluticasone
10/25/2001	CA2405563A1 Albumin fusion proteins
10/25/2001	CA2405557A1 Albumin fusion proteins
10/25/2001	CA2405550A1 Albumin fusion proteins
10/25/2001	CA2405525A1 Albumin fusion proteins
10/25/2001	CA2405385A1 Hair growth stimulant compositions with sustained action
10/25/2001	CA2403591A1 Pharmaceutical compositions comprising fluvastatin
10/24/2001	EP1148106A1 Pressure-sensitive adhesive composition and moisture-permeable pressure-sensitive adhesive tape, pressure-sensitive adhesive drug composition, and pressure-sensitive adhesive tape preparation each containing the composition
10/24/2001	EP1147781A1 Biodegradable implant precursor
10/24/2001	EP1147779A1 A method for rendering ursodeoxycholic acid in soluble form pharmaceutical compositions
10/24/2001	EP1147778A1 Stable gel formulation for topical treatment of skin conditions
10/24/2001	EP1147770A1 Virginiamycin mixture
10/24/2001	EP1147766A2 Pharmaceutical compositions
10/24/2001	EP1147148A1 Dextran-maleic acid monoesters and hydrogels based thereon
10/24/2001	EP1147138A1 Hydrophilic ampholytic polymer
10/24/2001	EP1146959A1 Method and apparatus for liposome production
10/24/2001	EP1146913A2 Conjugates of colony stimulating factors for targeting and imaging infection and inflammation
10/24/2001	EP1146908A1 Formulations comprising antisense nucleotides to connexins
10/24/2001	EP1146907A2 Use of cationic lipids to generate anti-tumor immunity
10/24/2001	EP1146906A1 Mucosal delivery system
10/24/2001	EP1146901A1 Potentiation of anti-cd38-immunotoxin cytotoxicity
10/24/2001	EP1146897A1 Use of a melanoma inhibiting activity factor (mia) for cartilage and bone repair
10/24/2001	EP1146896A2 Monodisperse hexameric acylated insulin analog formulations
10/24/2001	EP1146890A2 Buccal delivery system for proteinaceous medicaments
10/24/2001	EP1146876A2 Compositions having improved stability
10/24/2001	EP1146864A1 Ph independent extended release pharmaceutical formulation
10/24/2001	EP1146862A1 Pharmaceutical compositions
10/24/2001	EP1146861A1 Hydrogel particle formulations
10/24/2001	EP1146860A2 Polymeric delivery agents and delivery agent compounds
10/24/2001	EP1146857A2 Materials and methods for making improved micelle compositions
10/24/2001	EP1146856A1 Spheronised self-emulsifying system for hydrophobic and water-sensitive agents
10/24/2001	EP1146855A1 Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
10/24/2001	EP1146851A1 Galenic formulation containing biotin
10/24/2001	EP1146845A2 Compressed lecithin preparations
10/24/2001	EP0934593A4 Electrically conductive adhesive hydrogels
10/24/2001	EP0921791B1 Composition comprising mupirocin and chlorhexidine
10/24/2001	EP0904064B1 Oral pharmaceutical compositions containing sex hormones
10/24/2001	EP0847242B1 Sugar-free dragee-like products
10/24/2001	EP0844868B1 Compositions including O-carboxymethyl chitosan and use in ophthalmics
10/24/2001	EP0840555B1 Stabilisation of flavourants
10/24/2001	EP0818994B1 Method of making a pressure sensitive skin adhesive sheet material
10/24/2001	EP0723435B1 Once-a-day metoprolol oral dosage form
10/24/2001	EP0662833B1 Aqueous composition
10/24/2001	CN1319127A Water-soluble concentrate obtained for emulgator or water-solubilising phase and complex of liquid lipophile substances of plant origin
10/24/2001	CN1319016A Process for preparation of oral pharmaceutical compositions comprising biphosphonates
10/24/2001	CN1319015A Compositions containing diphosphonic acids
10/24/2001	CN1319011A Tumor tissue accumulation enhancers for drugs
10/24/2001	CN1319005A Pharmaceutical composition comprising entacapone or nitecapone as well as cross-linked cellulose derivative
10/24/2001	CN1319004A New pharmaceutical formulation
10/24/2001	CN1319003A Protein formulations
10/24/2001	CN1073419C Compound eye drops for preventing and treating eye infection and its preparation
10/24/2001	CN1073413C Transdermal therapeutic system and its prep.
10/23/2001	US6307025 VCAM fusion proteins and DNA coding therefor
10/23/2001	US6306993 Method and composition for enhancing transport across biological membranes
10/23/2001	US6306922 Macromer polymers crosslinked by photopolymerization
10/23/2001	US6306914 Progestin therapy for maintaining amenorrhea
10/23/2001	US6306902 Oxaliplatin formulations
10/23/2001	US6306898 Mixture of vitamin e and squalane for skin disorders
10/23/2001	US6306894 Seals on containers for piclitaxel and sealed containers and drugs
10/23/2001	US6306879 Isotonic glucose solution
10/23/2001	US6306856 Dissolving pyridonecarboxylic acid or salt, mixing with glycyrrhizic acid with acid
10/23/2001	US6306843 Solvents, solutions and mixtures of dimethylisosorbide, propylene glycol or diethylene glycol monoethyl ether, cyclic acid imide and/or sulfaminic acid of a compound of aromatic alcohol or ether
10/23/2001	US6306838 Targeted vesicular constructs for cyto protection and treatment of h. pylori
10/23/2001	US6306825 Cyclosporin galenic forms
10/23/2001	US6306789 Mucoadhesive granules of carbomer suitable for oral administration of drugs
10/23/2001	US6306626 Immunoglobulin; for use in preferential killing of hybridoma or lymphocytes
10/23/2001	US6306612 Methods of facilitating vascular growth
10/23/2001	US6306595 Design of drugs involving receptor-ligand-DNA interactions
10/23/2001	US6306440 Forming solution of insulin in solvent and a substance that enhances absorption of insulin in lower respiratory tract; removing solvent to obtain solid; forming into powder; incorporating powder into dry powder inhaler device
10/23/2001	US6306439 Expandable pharmaceutical forms
10/23/2001	US6306438 For therapy of pain; storgae stability
10/23/2001	US6306435 Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
10/23/2001	US6306429 Throat drops suitable for relief of cough and cold symptoms
10/23/2001	US6306428 Controlled active substance release is accomplished with rolled or folded layers of a polymer film, that contain a pharmaceutically active substance
10/23/2001	US6306425 Time release agents; therapy of drug abuse and drug dependence
10/23/2001	US6306423 Biocompatible implant for continuous in vivo release of a neurotoxin over a treatment period extending from one month to five years
10/23/2001	US6306421 Therapeutic inhibitor of vascular smooth muscle cells
10/23/2001	US6306420 Obtaining implantable device for automatic delivery of an active ingredient according to adjustable delivery profile; providing energy to controller and actuator to move drug from reservoir to transit area to deliver to body fluids
10/23/2001	US6306407 Cosmetics
10/23/2001	US6306406 Drug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer
10/23/2001	US6306398 Delipidating plant powder by extraction of powder with a solution containing organic solvent; separating powder from organic solvent; extracting delipidated powder with solvent or phosphate buffered saline; separation to obtain retentate
10/23/2001	US6306385 Method of protecting against chronic infections
10/23/2001	US6306383 Method for topical treatment of scars with protein kinase C inhibitors
10/23/2001	US6306345 Drying biological solution or suspension in a chamber by boiling under vacuum to form mechanically stable foam; crushing foam to form powder
10/23/2001	US6306243 pH-modified biocompatible monomer and polymer compositions
10/23/2001	CA2223817C Compositions for the treatment of rheumatoid-based arthritic diseases
10/23/2001	CA2203566C Percutaneously administration preparation
10/23/2001	CA2203310C Compressed matrix for slow release of salt of tianeptine sodium following oral administration

1 ... 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 ... 1712